PharmaTelevision - CM Capital: Mark Harvey shares his views on the best type of scenario for financing a company and why he is optomistic for the future.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: CM Capital: Mark Harvey shares his views on the best type of scenario for financing a company and why he is optomistic for the future.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Mark Harvey, Partner of CM Capital.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Types of investments

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech's convention in Adelaide. On this show I have Mark Harvey, who is the Partner or a Partner at CM Capital Investments which is based in Brisbane, welcome.

Mark Harvey:

Thank you.

Fintan Walton:

Mark, you're obviously a venture capitalist you invest in technologies I understand broad range of different technologies, but obviously you are here with your life sciences hat on at this particular convention, first of all just introduce our audience to your firm and the types of investments that you do.

Mark Harvey:

Yes sure, as you've seen Capital has been for 12-years now and it was started in '98 and we have raised three funds thus far and 250 million under management 21, 22 portfolio companies and they are spread across what we call texo in the ICT and then in security, but the majority of our investments have been in life sciences including pharmaceuticals, medical devices and diagnostics.

Fintan Walton:

Right, and what stage do you come in at are you an early stage investor or late stage investor?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Mark Harvey

Partner

At the time of recording this PTV interview Mark Harvey works as Partner of CM Capital. Mark joined CM Capital in April 2006 and has over 15 years experience in medical research, technology transfer and commercialization. He is involved in all aspects of life science investments. Mark has played key roles in the formation, fund raising and management of numerous life science companies including directorships, and has led the negotiations on numerous licensing and research collaboration deals. Prior to joining CM Capital, Mark was the Managing Director of Symbiosis Group Limited, an early stage life sciences investment company, and was Group Manager, Life Sciences for UniQuest, the commercial arm of the University of Queensland. In this role, Mark co-ordinated the commercialization of intellectual property assets in the field of life sciences (including biotechnology) at the University of Queensland. He was a member of the Investment Committee of UniSeed, a $60million pre-seed venture fund focused on the commercialization of technologies out of the University of Melbourne and The University of Queensland. Mark is also an Adjunct Associate Professor of The University of Queensland.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

CM Capital Investments

CM Capital is a venture capital firm specializing in investments in early, seed, and expansion and growth stages of a company's development. The firm seeks to invest in life sciences, medical devices, telecommunications, convergence of biotechnology and information technology, renewable energy, and biotechnology or chemistry sectors. It prefers to invest in companies based in Australia. The firm typically invests between AUD$500,000 ($380,000) and AUD$8 million ($6.45 million). It takes a board seat in its portfolio companies. CM Capital Investments was founded in 2007 and is based at Brisbane, Australia.